中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 7
Jul.  2019
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(7): 1546-1550

Clinical effect of glucocorticoids versus pentoxifylline in patients with severe alcoholic liver disease: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.07.025

  • Department of Severe Liver Disease, Beijing YouAn Hospital, Capital Medical University

Research funding:

 

  • Received Date: 2019-02-11
  • Published Date: 2019-07-20
    Abstract

  • Objective To systematically review the clinical effect of glucocorticoids used alone or in combination with pentoxifylline in patients with severe alcoholic liver disease. Methods PubMed, Embase, Chinese Scientific Journal Full-Text Database, CBM, China Scientific Journal Database, and Chinese Medical Association Digital Journal Database were searched for related articles published up to November 2018, and related journals and collected papers from conferences were searched manually. The clinical effect of glucocorticoids versus placebo, glucocorticoids versus pentoxifylline, and glucocorticoids combined with glucocorticoids versus glucocorticoids alone was analyzed.The effect of glucocorticoids and pentoxifylline used alone or in combination on 28-day survival rate and hepatorenal syndrome in patients with severe alcoholic liver disease was assessed. Odds ratio ( OR) and 95% confidence interval ( CI) were used to evaluate outcome indicators. RevMan 5. 3 software was used for data analysis. Results A total of 22 studies were included, with 1956 patients in total. The glucocorticoid group had a significantly lower 28-day mortality rate than the control group ( 25. 12% vs 30. 67%, OR = 0. 71, 95% CI: 0. 55-0. 93, P = 0. 01) . Subgroup analysis showed that there was a significant difference in 28-day mortality rate between the glucocorticoid group and the pentoxifylline group ( OR = 0. 68, 95% CI: 0. 48-0. 97, P = 0. 03) , while there was no significant difference between the glucocorticoid + pentoxifylline group and the glucocorticoid group ( OR = 0. 92, 95% CI: 0. 66-1. 29, P = 0. 64) . Compared with the glucocorticoid group, the glucocorticoid + pentoxifylline group had a significantly lower incidence rate of hepatorenal syndrome ( 3. 94% vs8. 03%, OR = 0. 45, 95% CI: 0. 24-0. 83, P = 0. 01) . Funnel plots showed no publication bias. Conclusion Glucocorticoids combined with pentoxifylline can reduce the incidence rate of hepatorenal syndrome in patients with severe alcoholic liver disease.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association.Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J].J Clin Hepatol, 2018, 34 (5) :939-946. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :939-946.
    [2]YANG S, XING HC, CHENG J.Comparison and interpretation of Chinese, American, and European guidelines on alcoholic liver diseases[J].J Clin Hepatol, 2018, 34 (7) :1420-1422. (in Chinese) 杨松, 邢卉春, 成军.中美欧酒精性肝病相关指南的对比与解读[J].临床肝胆病杂志, 2018, 34 (7) :1420-1422.
    [3]PARKER R, ARMSTRONG MJ, CORBETT C, et al.Systematic review:Pentoxifylline for the treatment of severe alcoholic hepatitis[J].Aliment Pharmacol Ther, 2013, 37 (9) :845-854.
    [4]THURSZ MR, RICHARDSON P, ALLISON M, et al.Prednisoloneor pentoxifylline for alcoholic hepatitis[J].N Engl J Med, 2015, 372 (17) :1619-1628.
    [5]BLITZER BL, MUTCHNICK MG, JOSHI PH, et al.Adrenocorticosteroid therapy in alcoholic hepatitis.A prospective, double-blind randomized study[J].Am J Dig Dis, 1977, 22 (6) :477-484.
    [6]BORIES P, GUEDJ JY, MIROZE D, et al.Treatment of acute alcoholic hepatitis with prednisolone 45 patients[J].Presse Med, 1987, 16 (16) :769-772.
    [7]CAMPRA JL, HAMLIN EM Jr, KIRSHBAUM RJ, et al.Prednisone therapy of acute alcoholic hepatitis.Report of a controlled trial[J].Ann Intern Med, 1973, 79 (5) :625-631.
    [8]CARITHERS RL Jr, HERLONG HF, DIEHL AM, et al.Methylprednisolone therapy in patients with severe alcoholic hepatitis.A randomized multicenter trial[J].Ann Intern Med, 1989, 110 (9) :685-690.
    [9]DEPEW W, BOYER T, OMATA M, et al.Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy[J].Gastroenterology, 1980, 78 (3) :524-529.
    [10]CABRE E, RODRIGUEZ-IGLESIAS P, CABALLERIA J, et al.Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition:A multicenter randomized trial[J].Hepatology, 2000, 32 (1) :36-42.
    [11]HELMAN RA, TEMKO MH, NYE SW, et al.Alcoholic hepatitis.Natural history and evaluation of prednisolone therapy[J].Ann Intern Med, 1971, 74 (3) :311-321.
    [12]LESESNE HR, BOZYMSKI EM, FALLON HJ.Treatment of alcoholic hepatitis with encephalopathy.Comparison of prednisolone with caloric supplements[J].Gastroenterology, 1978, 74 (2 Pt 1) :169-173.
    [13]MADDREY WC, BOITNOTT JK, BEDINE MS, et al.Corticosteroid therapy of alcoholic hepatitis[J].Gastroenterology, 1978, 75 (2) :193-199.
    [14]MENDENHALL CL, ANDERSON S, GARCIA-PONT P, et al.Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone[J].N Engl J Med, 1984, 311 (23) :1464-1470.
    [15]GOLDBERG SJ, MENDENHALL CL, CONNELL AM, et al.“Nonalcoholic”chronic hepatitis in the alcoholic[J].Gastroenterology, 1977, 72 (4 Pt 1) :598-604.
    [16]PORTER HP, SIMON FR, POPE CE 2nd, et al.Corticosteroid therapy in severe alcoholic hepatitis.A double-blind drug trial[J].N Engl J Med, 1971, 284 (24) :1350-1355.
    [17]RAMOND MJ, POYNARD T, RUEFF B, et al.A randomized trial of prednisolone in patients with severe alcoholic hepatitis[J].N Engl J Med, 1992, 326 (8) :507-512.
    [18]SHUMAKER JB, RESNICK RH, GALAMBOS JT, et al.A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis.With a note on published results in encephalopathic patients[J].Am J Gastroenterol, 1978, 69 (4) :443-449.
    [19]THEODOSSI A, EDDLESTON AL, WILLIAMS R.Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis[J].Gut, 1982, 23 (1) :75-79.
    [20]SIDHU SS, GOYAL O, SINGLA M, et al.Pentoxifylline in severe alcoholic hepatitis:A prospective, randomised trial[J].JAssoc Physicians India, 2012, 60:20-22.
    [21]DE BK, GANGOPADHYAY S, DUTTA D, et al.Pentoxifylline versus prednisolone for severe alcoholic hepatitis:A randomized controlled trial[J].World J Gastroenterol, 2009, 15 (13) :1613-1619.
    [22]PARK SH, KIM DJ, KIM YS, et al.Pentoxifylline vs.corticosteroid to treat severe alcoholic hepatitis:A randomised, non-inferiority, open trial[J].J Hepatol, 2014, 61 (4) :792-798.
    [23]MATHURIN P, LOUVET A, DUHAMEL A, et al.Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis:A randomized clinical trial[J].JAMA, 2013, 310 (10) :1033-1041.
    [24]LIN SF.Prospective clinical research of efficacy of pentoxifylline in the treatment of severe alcoholic hepatitis[J].Pract Pharm Clin Remedies, 2014, 17 (7) :924-926. (in Chinese) 林素芳.己酮可可碱治疗重症酒精性肝炎的前瞻性临床研究[J].实用药物与临床, 2014, 17 (7) :924-926.
    [25]LIN Y.Effect of pentoxifylline on severe alcoholic hepatitis[J].Strait Pharm J, 2011, 23 (11) :102-103.林雅.己酮可可碱治疗重症酒精性肝炎的疗效观察[J].海峡药学, 2011, 23 (11) :102-103.
    [26]KIM EJ, LEE JG, KIM JY, et al.Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets[J].Immunology, 2017, 152 (4) :628-637.
    [27]WANG XF, FENG GH.Research advances in glucocorticoids for the treatment of liver failure[J].J Clin Hepatol, 2018, 34 (7) :1565-1568. (in Chinese) 王秀芳, 冯国和.糖皮质激素治疗肝衰竭研究现状[J].临床肝胆病杂志, 2018, 34 (7) :1565-1568.
    [28]SUK KT, KIM MY, BAIK SK.Alcoholic liver disease:Treatment[J].World J Gastroenterol, 2014, 20 (36) :12934-12944.
    [29]LOUVET A, LABREUCHE J, ARTRU F, et al.Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis:A prospective study[J].Hepatology, 2017, 66 (5) :1464-1473.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (399) PDF downloads(183) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return